Home › Research › Digital health tools
GPS driving: a digital biomarker for preclinical Alzheimer disease
Bayat S, Babulal GM, Schindler SE, Fagan AM, Morris JC, Mihailidis A, Roe CM.. Alzheimer's research & therapy, 2021-06-14
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer disease (AD) is the most common cause of dementia. Preclinical AD is the period during which early AD brain changes are present but cognitive symptoms have not yet manifest. The presence of AD brain changes can be ascertained by molecular biomarkers obtained via imaging and lumbar puncture. However, the use of these methods is limited by cost, acceptability, and availability. The preclinical stage of AD may have a subtle functional signature, which can impact complex behaviours such as driving. The objective of the present study was to evaluate the ability of in-vehicle GPS data loggers to distinguish cognitively normal older drivers with preclinical AD from those without preclinical AD using machine learning methods. Methods We followed naturalistic driving in cognitively normal older drivers for 1 year with a commercial in-vehicle GPS data logger. The cohort included n = 64 individuals with and n = 75 without preclinical AD, as determined by cerebrospinal fluid biomarkers. Four Random Forest (RF) models were trained to detect preclinical AD. RF Gini index was used to identify the strongest predictors of preclinical AD. Results The F1 score of the RF models for identifying preclinical AD was 0.85 using APOE ε4 status and age only, 0.82 using GPS-based driving indicators only, 0.88 using age and driving indicators, and 0.91 using age, APOE ε4 status, and driving. The area under the receiver operating curve for the final model was 0.96. Conclusion The findings suggest that GPS driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults.
What this study adds
Evidence grade: Moderate
The record lists 64 participants. GPS driving data analyzed with machine learning distinguished cognitively normal older drivers with preclinical Alzheimer's disease from those without, with an F1 score of 0.91 when combining age, APOE ε4 status, and driving indicators. This is a potential digital biomarker for identifying preclinical Alzheimer's disease and does not treat, cure, or prevent the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bayat, S., Babulal, G. M., Schindler, S. E., Fagan, A. M., Morris, J. C., Mihailidis, A., et al. (2021). GPS driving: a digital biomarker for preclinical Alzheimer disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-021-00852-1
Vancouver
Bayat S, Babulal GM, Schindler SE, Fagan AM, Morris JC, Mihailidis A, et al. GPS driving: a digital biomarker for preclinical Alzheimer disease. Alzheimer's research & therapy. 2021. doi:10.1186/s13195-021-00852-1. PMID: 34127064.
BibTeX
@article{bayat2021-34127064,
author = {Bayat, S. and Babulal, G. M. and Schindler, S. E. and Fagan, A. M. and Morris, J. C. and Mihailidis, A. and Roe, C. M.},
title = {{GPS driving: a digital biomarker for preclinical Alzheimer disease}},
journal = {Alzheimer's research \& therapy},
year = {2021},
doi = {10.1186/s13195-021-00852-1},
pmid = {34127064},
url = {https://doi.org/10.1186/s13195-021-00852-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results The F1 score of the RF models for identifying preclinical AD was 0.85 using APOE ε4 status and age only, 0.82 using GPS-based driving indicators only, 0.88 using age and driving indicators, and 0.91 using age, APOE ε4 status, and driving.
- Conclusion The findings suggest that GPS driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults.
Why it matters
GPS driving data analyzed with machine learning distinguished cognitively normal older drivers with preclinical Alzheimer's disease from those without, with an F1 score of 0.91 when combining age, APOE ε4 status, and driving indicators. This is a potential digital biomarker for identifying preclinical Alzheimer's disease and does not treat, cure, or prevent the disease.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Participants64
- Evidence strengthModerate
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 64 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 91 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.0 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 5 / 6 | Cited 26.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 48 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Catherine M. Roe: h-index 51 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34127064) |
| Free to read | 2 / 2 | Free to read |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-021-00852-1
- PubMed: 34127064
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Digital health tools from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.